title: Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
abstract: The pharmacokinetics of the controlled-release preparation of disopyramide phosphate (Norpace CR, Searle Laboratories, Chicago, IL) were studied in ten patients with cardiac arrhythmias. Multiple-serum disopyramide concentrations were obtained after a 300-mg oral dose. Each patient then received chronic oral therapy with the controlled-release preparation (400 to 1000 mg/day) on an every-12-hour schedule. At steady state, disopyramide trough concentrations were obtained. Serum disopyramide concentrations were determined by high performance liquid chromatography. The regimen was well tolerated by all patients. The mean (+/- SD) time to maximum concentration, maximum concentration, and concentrations 11 and 24 hours after the initial dose were 5.5 +/- 1.3 hours and 2.8 +/- 0.8, 2.0 +/- 0.9, and 1.2 +/- 0.5 micrograms/mL, respectively. A low Cmax to trough concentration ratio of 1.35 +/- 0.26 was observed after the initial dose. Linear regression analysis of the serum disopyramide concentrations 11 hours after initial dose (trough) versus trough concentrations at steady state (dose adjusted) showed a strong correlation (r = 0.87, intercept = 0.03, and slope = 1.9). Regression analysis also showed a strong relationship between the area under the curve (AUC) from time 0 to 11 hours after the initial dose and the trough at steady state (r = 0.86).
  
  
  CONCLUSIONS
  The controlled-release preparation of disopyramide, when administered every 12 hours in patients with cardiac arrhythmias, should produce low peaks to trough fluctuations. Because disopyramide concentrations after the initial dose correlate well with trough concentrations at steady state, these concentrations may provide a simple and convenient method for prospective monitoring of disopyramide therapy in patients receiving the controlled-release preparation.
authors.affiliation: Drug Information Center, Hartford Hospital, CT 06115.
authors.forename: E V
authors.initials: EV
authors.lastname: Capparelli
authors.forename: D M
authors.initials: DM
authors.lastname: DiPersio
authors.forename: H
authors.initials: H
authors.lastname: Zhao
authors.forename: J
authors.initials: J
authors.lastname: Kluger
authors.forename: M S
authors.initials: MS
authors.lastname: Chow
mesh_terms: D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000378:metabolism*; D003692:Delayed-Action Preparations; D004206:Disopyramide / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male
chemical_list: D003692:Delayed-Action Preparations; D004206:Disopyramide